Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

Aerie Pharmaceuticals

Status and phase

Completed

Phase 2

Conditions

Open Angle Glaucoma

Ocular Hypertension

Treatments

Other: Netarsudil Ophthalmic Solution Vehicle

Drug: Netarsudil ophthalmic solution 0.02%

Study type

Interventional

Funder types

Industry

Identifiers

AR-13324-CS204

Details and patient eligibility

About

To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.

Enrollment

12 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

18 years of age or older.
Ocular hypertension or open-angle glaucoma in both eyes.
Unmedicated intraocular pressure > 17 mmHg in one or both eyes and < 30 mmHg in both eyes.
Corrected visual acuity in each eye equivalent to 20/200 or better.
Able and willing to give signed informed consent and follow study instructions.

Exclusion criteria

Glaucoma with pseudoexfoliation or pigment dispersion component, history of angle closure, narrow angles.
Intraocular pressure ≥ 30 mmHg.
Use of ocular medications within 30 days.
Known hypersensitivity to any component of the test formulations or to medications used routinely during a clinical eye examination.
Previous eye surgery (other than cataract).
Ocular trauma within 6 months.
Clinically significant ocular disease that might interfere with the study.
Central corneal thickness greater than 620 µm.